Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms MEDICARE
- 07 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.
- 30 Aug 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2018.